IndustryCompany release

Zimmer Biomet third-quarter sales rise 3.1% to $2.06bn as knees decline

🇺🇸 Zimmer Biomet Holdings, Inc. (ZBH) · Wed 04 Nov 2026

The orthopaedic device maker reported hip and technology-segment growth, a drop in knees, and raised its 2026 organic growth and adjusted earnings guidance.

Zimmer Biomet Holdings reported third-quarter 2026 results on 4 November, with net sales of $2.063bn. That is up 3.1% on a reported basis and 3.7% in constant currency, which strips out the effect of exchange-rate movements.

Performance was uneven across product categories. Hips grew, as did the company's technology, bone cement and surgical group, while knees declined.

Diluted earnings per share were $1.00, or $1.90 on an adjusted basis. The company also raised its 2026 guidance for organic constant-currency growth and for adjusted earnings per share.

The summary available to VigiEye does not give the revised guidance ranges or explain what drove the knee decline, so those details are not reported here.

What it means for your team

  • Market-access teams tracking orthopaedics should note that knees fell in the quarter while hips and the technology, bone cement and surgical group grew.
  • Teams relying on Zimmer Biomet supply or pricing assumptions should check the full results release for the revised guidance ranges and any segment commentary.
  • Constant-currency and reported growth differ here (3.7% against 3.1%), so comparisons should use the same basis.

Company's press release (SEC filing): Zimmer Biomet Holdings, Inc. ↗

Article written by VigiEye from the official source (Zimmer Biomet Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →